What they were paid
aTYR PHARMA Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | — | $0 | — | $0 | — |
| FY2024 | — | $0 | — | $0 | — |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: aTYR PHARMA INC DEF 14A filed March 26, 2026, accession 0001339970-26-000021, and prior-year filings. Open the filing on EDGAR.
Committees
FY2025 · as the proxy prints themAudit
The rest of the aTYR PHARMA board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Eric Benevich | Independent Director | $163,849 |
| Jane A. Gross, Ph.D | Independent Director | $170,423 |
| Paul Schimmel, Ph.D | Independent Director | $152,085 |
| Sanjay S. Shukla, M.D., M.S | Director | $0 |
| Sara L. Zaknoen, M.D | Independent Director | $167,422 |
| Svetlana Lucas, Ph.D | Independent Director | $175,129 |
The full aTYR PHARMA compensation record
free company briefThis page is one director within aTYR PHARMA's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat